How to compare GLP-1 telehealth platforms in 2026

What 1,251 adults ranked when they picked a platform

A U.S. News & World Report survey asked 1,251 U.S. adults who had received a GLP-1 medication through a telehealth platform in the past 12 months how they chose that platform. The article is dated 19 October 2026. The methodology says PureSpectrum fielded the survey in May and June 2026. Of the respondents, 54% identified as male and 46% as female, and ages 25 to 44 were 63% of the sample. The press release the same day says the survey covered more than 1,200 adults, which is the rounded form of 1,251.

The article's selection table is the decision list. People were asked what they ranked as most important. Screening, follow-up, and cost transparency are the top three. Lifestyle support and side-effect support are the bottom two. The press release uses a shorter label, quality of medical follow-ups, for the 26% row, and it calls 4% and 7% the lowest enrollment priorities.

Screening is the item 29 percent put first

A U.S. News & World Report survey puts a thorough initial screening at 29%, ahead of every other item in the selection table. The article quotes Dr. Fatima Cody Stanford, identified as an obesity medicine physician at Massachusetts General Hospital and Harvard Medical School, on what that kind of assessment can include: treatment goals, current medications, kidney function if indicated, prior pancreatitis or gallbladder disease, diabetic eye disease, nutritional status, eating disorders, pregnancy plans, and personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. The same quotation says doctors often order baseline bloodwork, including hemoglobin A1C, fasting glucose, a comprehensive metabolic panel, a fasting lipid panel, and thyroid hormone.

That list is the physician's description in the survey article. It is not a panel this site assigns to a reader, and it is not a score for any provider in the catalog. The comparison use is narrower. Before paying, the useful question is whether the platform's own page says a licensed clinician reviews the intake before a prescription, and whether it names what that review covers. A price with no screening description has not answered the item 29% of respondents ranked first.

Follow-up is the second rank, and support is a switch reason

Quality of medical follow-ups and support is 26% in the same U.S. News & World Report survey, the second selection rank. Lack of support is also the second switch reason, at 36% of the 341 respondents who had tried a different weight-loss platform. The press release calls that a lack of support and pairs it with high prices as the primary switching reasons. The two numbers answer different questions. The 26% is what people say they look for when they enroll. The 36% is what people who left a platform say was missing.

The survey article also reports self-reported weight change and ties some of it to behavioral support. This note does not use those answers as a result of any drug or any platform. Follow-up, for a price comparison, is a published fact: whether the page says the fee includes later visits, messaging, or refills, and whether that access is in the same bill as the medication. The provider profile and the program table are where those facts are checked. They do not turn a follow-up promise into a predicted outcome.

A survey association between support and self-reported weight change is not a clinical result for a named drug.

Cost transparency is the third rank, and the later price is the one to read

Cost transparency is 23% in the U.S. News & World Report selection table, just behind follow-up. The survey article quotes Dr. Jeffrey Egler, identified there as chief medical officer at Noom, on introductory prices: low introductory prices get people onto the medication, and after the first month the price goes up. He says people then find they cannot afford it. Noom is named because that is how the article identifies him. This note does not link Noom as an offer.

An introductory month and the next bill are different numbers. The month-one versus month-two page on this site keeps them apart: month one is the introductory price when one is recorded, and the continuing price when it is not. A 4-week plan stays on its 4-week charges. A prepaid effective rate is not used as either month. The note on why a GLP-1 price rises after month one separates introductory rates, manufacturer offers, dose ladders, and prepaid conditions. The note on whether the price includes the medication separates a membership fee, an all-inclusive checkout price, and a dose-based price that appears only after a prescriber picks a strength. Cost transparency, in the survey's word, is whether those pieces are visible before payment.

Cost and lack of support led the switch reasons

A U.S. News & World Report survey says 31% of the 1,251 respondents had tried more than one GLP-1 telehealth platform. Separately, 341 respondents said they had previously tried a different weight-loss platform and gave reasons. The press release reports the 31%, the 57%, and the 36%, and it says high prices rather than the table's shorter label, cost.

The article states the 31% and the 341 as separate figures. Thirty-one percent of 1,251 is about 388 people, so the 341 who gave reasons are a different count from the 31%. The logistics of leaving are a different page. A compounded prescription stays with the old program's pharmacy, a brand prescription can be sent to the manufacturer pharmacy by a new prescriber, and prepaid months follow the old program's written terms. That checklist is the switching note. The survey table is the list of reasons people gave.

The weight-loss row is a reason respondents selected. It is not a measured effect of a drug.

Where to check those items on this site

The comparison note already on this site says to start with the exact product, then the complete recurring cost, the commitment, clinical access, pharmacy disclosure, state eligibility, and cancellation terms. It does not name a best provider. That order lines up with the survey's top ranks without turning the survey into a ranking of this catalog. Screening and follow-up are read on the provider's own page and on the provider profile. Cost transparency is read on the program table: medication included or not, month one versus the later month, and any prepaid term.

The live module on this page is the current compounded semaglutide, compounded tirzepatide, Wegovy, and Zepbound comparison. Compounded semaglutide and compounded tirzepatide are not FDA-approved versions of the brands. A row can be a prepaid rate or a comparison listing when that is how the offer is stored. GobyMeds is a comparison listing, not a commission link. Use the program pages for the full tables, and the cheapest semaglutide page for that product's published low. The survey does not say which of those rows a respondent used.